Par Pharmaceutical Companies Inc.
http://www.parpharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Par Pharmaceutical Companies Inc.
FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle
Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.
Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition
Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.
Hikma Gets FTC Nod For Custopharm Deal – But With Strings Attached
Hikma has moved closer to completing a deal worth more than $400m to acquire Custopharm, which promises to bolster its US injectables business. However, the FTC’s approval of the transaction comes with conditions.
Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge
The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.
Company Information
- Other Names / Subsidiaries
-
- Anchen Pharmaceuticals, Inc.
- Edict Pharmaceuticals Private Limited
- JHP Pharmaceuticals, LLC
- Strativa Pharmaceuticals
- TPG Capital LP